Visfatin is upregulated in type-2 diabetic rats and targets renal cells (Q43106569)

14 November 2017

Visfatin is upregulated in type-2 diabetic rats and targets renal cells (English)

1 reference

14 November 2017

Young Sun Kang

1

1 reference

14 November 2017

Hye Kyoung Song

2

1 reference

14 November 2017

Mi Hwa Lee

3

1 reference

14 November 2017

Gang Jee Ko

4

1 reference

14 November 2017

Jee Young Han

5

1 reference

14 November 2017

Sang Youb Han

6

1 reference

14 November 2017

Kum Hyun Han

7

1 reference

14 November 2017

Hyoung Kyu Kim

8

1 reference

14 November 2017

Dae Ryong Cha

9

1 reference

14 November 2017

language of work or name

English

0 references

publication date

14 April 2010

1 reference

14 November 2017

1 reference

14 November 2017

78

1 reference

14 November 2017

2

1 reference

14 November 2017

170-181

1 reference

https://scigraph.springernature.com/pub.10.1038/ki.2010.98

14 November 2017

0 references

cites work

Cross-talk between the kidney and the cardiovascular system

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

American Society of Nephrology Presidential Address 2006: chronic kidney disease as a public health threat--new strategy for a growing problem

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

The emerging role of adipokines as mediators of inflammation and immune responses

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

Positional cloning of the mouse obese gene and its human homologue

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

Plasma visfatin concentrations and fat depot-specific mRNA expression in humans

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

Visfatin: a new player in mesangial cell physiology and diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

Adipose tissue as an endocrine organ

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

Visfatin--a true or false trail to type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

An update on visfatin/pre-B cell colony-enhancing factor, an ubiquitously expressed, illusive cytokine that is regulated in obesity

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

Genomic insights into acute inflammatory lung injury

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

Circulating visfatin level is correlated with inflammation, but not with insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

Plasma levels of PBEF/Nampt/visfatin are decreased in patients with liver cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

Visfatin is an adipokine, but it is not regulated by thiazolidinediones

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

Change of visfatin, C-reactive protein concentrations, and insulin sensitivity in patients with hyperthyroidism

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

High glucose elevates c-fos and c-jun transcripts and proteins in mesangial cell cultures

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

Glucose enhances type IV collagen production in cultured rat glomerular mesangial cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

The release of the adipocytokine visfatin is regulated by glucose and insulin.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

The human glomerular podocyte is a novel target for insulin action

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

Family of glucose-transporter genes. Implications for glucose homeostasis and diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

Angiotensin II stimulates the synthesis of vascular endothelial growth factor through the p38 mitogen activated protein kinase pathway in cultured mouse podocytes.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

Characterization of a renal tubular epithelial cell line which secretes the autologous target antigen of autoimmune experimental interstitial nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.98

7 January 2021

Identifiers

DOI

10.1038/KI.2010.98

1 reference

Dimensions Publication ID

14 November 2017

0 references

1 reference